Bromalex may be available in the countries listed below.
Ingredient matches for Bromalex
Bromazepam is reported as an ingredient of Bromalex in the following countries:
- Portugal
International Drug Name Search
Bromalex may be available in the countries listed below.
Bromazepam is reported as an ingredient of Bromalex in the following countries:
International Drug Name Search
tol-NAF-tate
In the U.S.
In Canada
Available Dosage Forms:
Therapeutic Class: Antifungal
Tolnaftate belongs to the group of medicines called antifungals. It is used to treat some types of fungus infections. It may also be used together with medicines taken by mouth for fungus infections.
Tolnaftate is available without a prescription.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For tolnaftate, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to tolnaftate or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Tolnaftate should not be used on children up to 2 years of age, unless otherwise directed by your doctor. Although there is no specific information comparing use of tolnaftate in children 2 years of age and older with use in other age groups, tolnaftate is not expected to cause different side effects or problems in children 2 years of age and older than it does in adults.
Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of tolnaftate in the elderly with use in other age groups.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
Before applying tolnaftate, wash the affected area and dry thoroughly. Then apply enough medicine to cover the affected area.
Keep tolnaftate away from the eyes.
For patients using the powder form of tolnaftate:
For patients using the aerosol powder form of tolnaftate:
For patients using the solution form of tolnaftate:
For patients using the aerosol solution form of tolnaftate:
To help clear up your infection completely, keep using tolnaftate for 2 weeks after burning, itching, or other symptoms have disappeared , unless otherwise directed by your doctor. Do not miss any doses.
The dose of tolnaftate will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of tolnaftate. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of tolnaftate, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Store the canister at room temperature, away from heat and direct light. Do not freeze. Do not keep tolnaftate inside a car where it could be exposed to extreme heat or cold. Do not poke holes in the canister or throw it into a fire, even if the canister is empty.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
If your skin problem does not improve within 4 weeks, or if it becomes worse, check with your health care professional.
To help prevent reinfection after the period of treatment with tolnaftate, the powder or spray powder form of tolnaftate may be used each day after bathing and carefully drying the affected area.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
When you apply the aerosol solution form of tolnaftate, a mild temporary stinging may be expected.
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: tolnaftate Topical side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Livifem may be available in the countries listed below.
Tibolone is reported as an ingredient of Livifem in the following countries:
International Drug Name Search
toe-si-LIZ-oo-mab
Patients treated with tocilizumab are at increased risk for infections, some progressing to serious infections leading to hospitalization or death. These infections have included bacterial sepsis, tuberculosis, and invasive fungal and other opportunistic infections. Evaluate for latent tuberculosis and treat if necessary prior to initiation of therapy. Monitor patients receiving tocilizumab for signs and symptoms of infection, including tuberculosis, even if initial latent tuberculosis test is negative .
In the U.S.
Available Dosage Forms:
Therapeutic Class: Immunological Agent
Pharmacologic Class: Monoclonal Antibody
Tocilizumab injection is a monoclonal antibody. It is used alone or together with other medicines to reduce the signs and symptoms of moderate to severe rheumatoid arthritis. Tocilizumab helps keep joint damage from getting worse after other medicines (e.g., adalimumab, etanercept, infliximab) have been used and did not work well.
Tocilizumab injection is also used to treat systemic juvenile idiopathic arthritis (SJIA) in children 2 years of age and older.
tocilizumab is available only with your doctor's prescription.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For tocilizumab, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to tocilizumab or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of tocilizumab injection in children with SJIA. However, safety and efficacy have not been established in children younger than 2 years of age.
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of tocilizumab injection in the elderly. However, elderly patients are more likely to have serious infections, which may require caution in patients receiving tocilizumab injection.
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | C | Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women. |
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving tocilizumab, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using tocilizumab with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of tocilizumab. Make sure you tell your doctor if you have any other medical problems, especially:
A nurse or other trained health professional will give you tocilizumab. tocilizumab is given through a needle placed in one of your veins. tocilizumab must be given slowly, so the needle will remain in place for at least one hour.
tocilizumab should come with a Medication Guide. It is very important that you read and understand this information. Be sure to ask your doctor about anything you do not understand.
It is very important that your doctor check your or your child's progress at regular visits to make sure that tocilizumab is working properly. Blood tests may be needed to check for unwanted effects.
Tell your doctor if you are pregnant or if you plan to become pregnant. If you become pregnant while receiving tocilizumab, your doctor may want you to join a registry for pregnant patients.
You will need to have a skin test for tuberculosis before you or your child start using tocilizumab. Tell your doctor if you or anyone in your home has ever had a positive reaction to a tuberculosis skin test.
tocilizumab may increase your risk of developing infections. Avoid being near people who are sick or have infections while you or your child are using tocilizumab. Wash your hands often. Tell your doctor if you have any kind of infection before you start using tocilizumab. Also tell your doctor if you have ever had an infection that would not go away or an infection that kept coming back.
Using tocilizumab may increase your risk of having certain cancers. Talk to your doctor if you or your child have concerns about this risk.
Call your doctor right away if you or your child start to have a cough that won't go away, weight loss, night sweats, fever, chills, or flu-like symptoms, such as a runny or stuffy nose, headache, blurred vision, or feeling generally ill. These may be signs that you have an infection.
Tocilizumab may cause headaches and skin reactions, such as a rash or itching, while you are receiving the injection or within 24 hours after you receive it. Check with your doctor or nurse right away if you or your child have any of these symptoms.
tocilizumab may cause a serious type of allergic reaction called anaphylaxis. Anaphylaxis can be life-threatening and requires immediate medical attention. Tell your doctor right away if you or your child have a rash; hives; itching; swelling of the face, tongue, and throat; trouble breathing; or chest pain after you receive the medicine.
tocilizumab may cause serious stomach and bowel problems, especially if you have a history of ulcers or diverticulosis. Check with your doctor right away if you or your child start having severe stomach cramps or pain; black, tarry stools; diarrhea; fever; or vomiting that is severe and sometimes bloody while being treated with tocilizumab.
While you or your child are being treated with tocilizumab, and after you stop treatment, do not have any immunizations (vaccines) without your doctor's approval. Tocilizumab may lower your body's resistance, and there is a chance you might get the infection the immunization is meant to prevent. In addition, other persons living in your household should not get live vaccines (e.g., nasal flu virus vaccine). Try to avoid being around persons who have received live vaccines. Do not get close to them and do not stay in the same room with them for very long. If you or your child cannot take these precautions, you should wear a protective face mask that covers the nose and mouth. Talk to your doctor if you have questions about this.
Your child's vaccines need to be current before he or she begins using tocilizumab injection. Be sure to ask your child's doctor if you have any questions about this.
tocilizumab may increase the level of cholesterol and fats in your blood. If this condition occurs, your doctor may give you a medicine to lower the cholesterol and fats. Talk to your doctor if you or your child have concerns.
Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: tocilizumab Intravenous side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
Raserpril may be available in the countries listed below.
Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Raserpril in the following countries:
International Drug Name Search
Relieving symptoms of sinus congestion, runny nose, sneezing, and cough due to colds, upper respiratory infections, and allergies. It may also be used for other conditions as determined by your doctor.
Tussi-12 S Suspension is an antihistamine and cough suppressant combination. The antihistamine works by blocking the action of histamine, which helps reduce symptoms, such as watery eyes and sneezing. The cough suppressant works in the brain to help decrease the cough reflex to reduce a dry cough.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Tussi-12 S Suspension. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Tussi-12 S Suspension. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Tussi-12 S Suspension may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Tussi-12 S Suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Tussi-12 S Suspension.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Constipation; diarrhea; dizziness; drowsiness; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor; trouble sleeping; vision changes.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
See also: Tussi-12 S side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; hallucinations; seizures; severe dizziness, lightheadedness, or headache; severe drowsiness; unusually fast, slow, or irregular heartbeat; vomiting.
Store Tussi-12 S Suspension at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Tussi-12 S Suspension out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Tussi-12 S Suspension. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
Fluoresceine Oxybuprocaine Faure may be available in the countries listed below.
Fluorescein sodium (a derivative of Fluorescein) is reported as an ingredient of Fluoresceine Oxybuprocaine Faure in the following countries:
Oxybuprocaine hydrochloride (a derivative of Oxybuprocaine) is reported as an ingredient of Fluoresceine Oxybuprocaine Faure in the following countries:
International Drug Name Search
Lamogine may be available in the countries listed below.
Lamotrigine is reported as an ingredient of Lamogine in the following countries:
International Drug Name Search
Class: Antineoplastic Agents
VA Class: AN900
Chemical Name: (±) - N - [4 - cyano - 3 - (trifluoromethyl)phenyl] - 3 - [(4 - fluorophenyl)sulfonyl] - 2 - hydroxy - 2 - methylpropanamide
Molecular Formula: C18H14F4N2O4S
CAS Number: 90357-06-5
Brands: Casodex
Antineoplastic agent; a nonsteroidal antiandrogen.1 3 4 14 40 43
Palliative treatment of metastatic (stage D2) prostate cancer; should be used in conjunction with a luteinizing hormone-releasing hormone (LHRH) analog (e.g., goserelin, leuprolide acetate).1 2 3 9 18
Initiate bicalutamide and LHRH analog concomitantly.1 35 43
Administer orally once daily at the same time each day (morning or evening) without regard to meals.1 35 43
50 mg once daily.1 3 9 40 43 Duration of combined therapy with LHRH analog depends on clinical response.35
Known hypersensitivity to bicalutamide or any ingredient in the formulation.1
Should not be used in women, particularly for conditions that are not serious or life-threatening.1
Women who are or may become pregnant.1 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)
May cause fetal harm; contraindicated in pregnant women.1
If used during pregnancy or if patient becomes pregnant, apprise of potential fetal hazard.1
Severe liver injury reported, sometimes resulting in hospitalization and/or death;1 26 manifestations generally occurred within first 3–4 months.1
Possible hepatitis or marked increases in serum concentrations of hepatic transaminases.1
Measure serum transaminase concentrations prior to initiation of therapy, at regular intervals during the first 4 months, and periodically thereafter.1
Immediately measure serum transaminase (especially ALT) concentrations if manifestations suggestive of liver dysfunction occur.1
Immediately discontinue if jaundice develops or serum ALT concentration is >2 times ULN; monitor liver function closely thereafter.1
Regularly monitor serum PSA to assess response; if PSA increases, evaluate for possible disease progression.1 17
For patients with objective progression of disease and elevated serum PSA, consider temporarily withdrawing bicalutamide while continuing LHRH analog.1 35 36 37 Withdrawal of bicalutamide may be associated with PSA decrease.31 44
Ensure accuracy of prescription; similarity in spelling of Casodex (the trade name for bicalutamide) and Kapidex (former trade name for dexlansoprazole, a proton-pump inhibitor) may result in errors.217 218 219 223
Category X.1 (See Fetal/Neonatal Morbidity and Mortality and also Contraindications under Cautions.)
Not known whether bicalutamide is distributed into milk;1 use caution.1
Safety and efficacy not established.1
Use with caution in patients with moderate to severe hepatic impairment.1 3
Consider periodic liver function tests in patients with hepatic impairment receiving long-term therapy.1 35
Not intended for use in women, particularly for nonserious or nonlife-threatening conditions.1
Combined therapy with LHRH analog: hot flashes, pain (including abdominal, back, and pelvic pain), asthenia, constipation, infection, nausea, dyspnea, diarrhea.1
Gynecomastia and breast pain frequent if bicalutamide used as monotherapy.1
Does not induce CYP isoenzymes.1 Pharmacokinetic interaction unlikely with drugs metabolized by CYP isoenzymes.1
Drug | Interaction | Comments |
|---|---|---|
Alcohol | Increased risk of facial flushing41 | Avoid alcohol consumption during therapy41 |
LHRH analog (e.g., goserelin, leuprolide) | Pharmacokinetic interaction unlikely1 | |
Warfarin and other coumarins | Decreased anticoagulant protein binding and increased plasma concentrations; increased anticoagulant effects1 | Monitor PT; adjust anticoagulant dosage as needed1 |
Well-absorbed following oral administration; absolute bioavailability is unknown.1
Food has no clinically important effect on rate or extent of absorption.1
96%.1
Undergoes stereospecific metabolism in the liver.1
Active R-enantiomer is predominantly oxidized to an inactive metabolite followed by glucuronidation.1 Inactive S-enantiomer is principally metabolized by glucuronidation.1
S-enantiomer is rapidly cleared relative to the R-enantiomer; R-enantiomer accounts for about 99% of total steady-state plasma concentrations.1
Both parent and metabolite glucuronides are eliminated in urine and feces.1
Approximately 6 days.1
Half-life of R-enantiomer was increased approximately 76% in patients with severe hepatic impairment.1
20–25°C.1
A selective antiandrogen with no androgenic or progestational activity in various animal models.12 17 43
Competitively blocks nuclear androgen receptors in target tissues (e.g., adrenal cortex, prostate, seminal vesicles).1 11 12 14 16 34 43
Blockade of androgen receptors in the hormone-sensitive tumor cells may result in growth arrest or transient tumor regression through inhibition of androgen-dependent DNA and protein synthesis.1 11 12 14 16 34 43
Inhibits initial androgenic stimulation and potential exacerbation of symptoms (e.g., bone pain, urinary obstruction, liver pain, impending spinal cord compression) associated with the first month of LHRH analog therapy.8 10 14 16 18 21 23 25 40
Risk of potential liver toxicity.1
Risk of facial flushing,1 41 particularly if used in conjunction with alcohol.41 Avoidance of alcohol recommended if flushing occurs.41
Importance of initiating bicalutamide concomitantly with LHRH analog and of not interrupting or discontinuing therapy without consulting a clinician.1
If used in women, importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.1
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as concomitant illnesses.1
Importance of informing patients of other important precautionary information.1 (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
|---|---|---|---|---|
Oral | Tablets, film- coated | 50 mg | Casodex | AstraZeneca |
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Bicalutamide 50MG Tablets (TEVA PHARMACEUTICALS USA): 30/$59.99 or 90/$159.97
Casodex 50MG Tablets (ASTRAZENECA): 30/$536.99 or 90/$1608.02
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions August 2010. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. AstraZeneca. Casodex (bicalutamide) tablets prescribing information. Wilmington, DE; 2002 Sep.
2. Anon. Drugs of choice for cancer chemotherapy. Med Lett Drugs Ther. 2000; 42: 83-92.
3. Blackledge G. Casodexmechanisms of action and opportunities for usage. Cancer. 1993; 72(Suppl):3830-3. [IDIS 323230] [PubMed 7504578]
4. Cockshott ID, Sotaniemi EA, Cooper KJ et al. The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. Br J Clin Pharmacol. 1993; 36:339-43. [IDIS 321958] [PubMed 12959312]
5. Wilson JD. Androgens. In: Gilman AG, Rall TW, Nies AS et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990:1413-1430.
6. Prostate cancer. From: CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Oct.
7. Schering. Eulexin (flutamide) capsules prescribing information (dated 1994 Jul). In: Physicians’ desk reference. 49th ed. Montvale, NJ: Medical Economics Company Inc; 1995:2253-4.
8. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989; 321:419-24. [IDIS 258377] [PubMed 2503724]
9. Schellhammer P, Sharifi R, Block N et al et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology. 1995; 45:745-52. [PubMed 7538237]
10. Dole EJ, Holdsworth MT. Nilutamide: an anitandrogen for the treatment of prostate cancer. Ann Pharmacother. 1997; 31: 65-75.
11. Geller J. Basis for hormonal management of advanced prostate cancer. Cancer. 1993; 71(Suppl):1039-45. [IDIS 313140] [PubMed 7679038]
12. McLeod DG. Antiandrogenic drugs. Cancer. 1993; 71(Suppl):1046-9. [IDIS 313141] [PubMed 8428326]
13. Migliari R, Muscas G, Usai E. Effect of Casodex on sleep-related erections in patients with advanced prostate cancer. J Urol. 1992; 148:338-41. [IDIS 300700] [PubMed 1378907]
14. Denis L. Prostate cancer: primary hormonal treatment. Cancer. 1993; 71(Suppl):1050-8. [IDIS 313142] [PubMed 8428327]
15. Smith PH. Deferred therapy in patients with advanced disease. Cancer. 1993; 71(Suppl):1074-7. [IDIS 313144] [PubMed 8428330]
16. Daneshgari F, Crawford ED. Endocrine therapy of advanced carcinoma of the prostate. Cancer. 1993; 71(Suppl):1089-97. [IDIS 313146] [PubMed 8428333]
17. Soloway MS, Matzkin H. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer. 1993; 71(Suppl):1083-8. [IDIS 313145] [PubMed 8428332]
18. Mahler C. Is disease flare a problem? Cancer. 1993; 72(Suppl):3799-802. (IDIS 323226)
19. Sagalowsky AI, Wilson JD. Hyperplasia and carcinoma of the prostate. In: Wilson JD, Braunwald E, Isselbacher KJ et al, eds. Harrison’s principles of internal medicine. 12th ed. New York: McGraw-Hill Company; 1991: 1629-33.
20. Brendler CB. Diseases of the prostate. In: Wyngaarden JB, Smith LH Jr, Bennett JC, eds. Cecil textbook of medicine. 19th ed. Philadelphia: WB Saunders Company; 1992:1351-5.
21. Chrisp P, Goa KL. Goserelin: a review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions. Drugs. 1991; 41:254-88. [PubMed 1709853]
22. Vogelzang NJ, Kennealey GT. Recent developments in endocrine treatment of prostate cancer. Cancer. 1992; 70:966-76. [IDIS 300575] [PubMed 1386283]
23. Santen RJ. Endocrine treatment of prostate cancer. J Clin Endocrinol Metab. 1992; 75:685-9. [IDIS 302863] [PubMed 1517354]
24. Tyrrell CJ, Altwein JE, Klippel F et al et al. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J Urol. 1991; 146:1321-6. [IDIS 290344] [PubMed 1834864]
25. Kuhn JM, Billebaud T, Navratil H et al. Prevention of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med. 1989; 321:413-8. [IDIS 258376] [PubMed 2503723]
26. Dawson LA, Chow E, Morton G. Fulminant hepatic failure associated with bicalutamide. Urology. 1997; 49:283-4. [PubMed 9037299]
27. Soloway MS. Newer methods of hormonal therapy for prostate cancer. Urology. 1984; 24(Suppl):30-8. [IDIS 198972] [PubMed 6437034]
28. Paulson DF. Management of metastatic prostatic cancer. Urology. 1985; 25:(Suppl):49-52.
29. Tolis G, Ackman D, Stellos A et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Med Sci. 1982; 79:1658-62.
30. Elder JS, Catalona WJ. Management of newly diagnosed metastatic carcinoma of the prostate. Urol Clin North Am. 1984; 11:283-95. [PubMed 6428022]
31. Nieh PT. Withdrawal phenomenon with the antiandrogen casodex. J Urol. 1995; 153:1070-2. [IDIS 342239] [PubMed 7531785]
32. Crawford ED. Withdrawal phenomenon with the antiandrogen Casodex: editorial comments. J Urol. 1995; 153:1072.
33. Scher HI, Kelly WK. Withdrawal phenomenon with the antiandrogen Casodex: editorial comments. J Urol. 1995; 153:1072-3.
34. Kennealey GT, Furr BJA. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma. Urol Clin North Am. 1991; 18:99-110. [PubMed 1992575]
35. Zeneca Pharmaceuticals, Wilmington, DE: Personal communication.
36. Cersosimo RJ, Carr D. Prostate cancer: current and evolving strategies. Am J Health-Syst Pharm. 1996; 53:381-96. [IDIS 360612] [PubMed 8673658]
37. McLeod DG, Kolvenbag GJCM. Defining the role of antiandrogens in the treatment of prostate cancer. Urology. 1996; 47(Suppl 1A):85-9. [PubMed 8560682]
39. Erlichman C, Loprinzi CL. Hormonal therapies. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 5th ed. Philadelphia, PA: J. B. Lippincott; 1997:395-405.
40. Anon. Bicalutamide for prostate cancer. Med Lett Drugs Ther. 1996; 38:56-7. [PubMed 8657047]
41. Kirschenbaum A. Management of hormonal treatment effects. Cancer. 1995; 75:1983-6.
42. Schellhammer PF, Sharifi R, Block NL et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology. 1997; 50:330-6. [PubMed 9301693]
43. Goa KL, Spencer CM. Bicalutamide in advanced prostate cancer: a review. Drugs Aging. 1998; 12:401-22. [PubMed 9606617]
44. Culig Z, Hoish A, Hittmair A et al. Androgen receptor gene mutations in prostate cancer: implications for disease progression and therapy. Drug Aging. 1997; 10:50-8.
217. US Food and Drug Administration. FDA approves name change for heartburn drug Kapidex. Rockville, MD; 2010 Mar 4. News release from FDA website ().
218. Institute for Safe Medication Practices. Kapidex-Casodex confusion. ISMP Medication Safety Alert! Community/Ambulatory Care edition. Horsham, PA; 2009 Jul. From ISMP website ().
219. Institute for Safe Medication Practices. ISMP quarterly action agenda July–September 2009. ISMP Medication Safety Alert! Acute Care edition. Horsham, PA; 2009 Oct 8. From ISMP website ().
222. Takeda Pharmaceuticals America. Dexilant (dexlansoprazole) delayed-release capsules prescribing information. Deerfield, IL; 2010 Mar.
223. Institute for Safe Medication Practices. Progress with preventing name confusion errors. ISMP Medication Safety Alert! Acute Care edition. Horsham, PA; 2007 Aug 9. From ISMP website ().
Zolpidemtartraat Losan may be available in the countries listed below.
Zolpidem tartrate (a derivative of Zolpidem) is reported as an ingredient of Zolpidemtartraat Losan in the following countries:
International Drug Name Search
Preventing or treating symptoms of hay fever and other upper respiratory allergies or the common cold, such as runny nose, sneezing, itching of the nose and throat, and itchy, watery eyes, and relieving cough. It may also be used for other conditions as determined by your doctor.
Triprolidine Syrup is an antihistamine. It works by blocking the action of histamine, reducing the symptoms of an allergic reaction.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with Triprolidine Syrup. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with Triprolidine Syrup. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if Triprolidine Syrup may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use Triprolidine Syrup as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Triprolidine Syrup.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Dizziness; drowsiness; dry mouth, throat, and nose; excitability; thickening of mucus in nose or throat.
Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); convulsions; fast heartbeat or pounding in the chest; decreased alertness; hallucinations; tremor; wheezing.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects at http://www.fda.gov/medwatch .
See also: Triprolidine side effects (in more detail)
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include coma; excitement; hallucinations; loss of consciousness; muscle twitching; seizures; tremor; weakness.
Store Triprolidine Syrup at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Triprolidine Syrup out of the reach of children and away from pets.
This information is a summary only. It does not contain all information about Triprolidine Syrup. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.
FOR COMMERCIAL USE ONLY
KEEP OUT OF REACH OF CHILDREN
NOT FOR HUMAN USE
CAUTION
Harmful if swallowed, eye irritant.
Avoid contact with skin and eyes. Contact can cause severe irritation. Get medical attention. If ingested, drink large amounts of water or milk. DO NOT induce vomiting. Get immediate attention. Avoid repeated contact with skin and hands. Use rubber gloves to avoid skin irritation. If contact occurs, wash thoroughly with clean water.
EMERGENCY : CHEMTREC 800-424-9300
Prior to milking, dip teats in undiluted Teat Dip HP 5. Wipe off with a clean towel after 15-30 seconds. After milking reapply Teat Dip HP 5. Do not rinse or wash off. Allow teats to dry before letting cows outdoors in cold weather to guard against.
Teat Dip HP 5
Non-Iodine Teat Dip
An Aid Reducing the Spread of Organisms
Which May Cause Mastitis
ACTIVE INGREDIENTS:
Hydrogen Peroxide........................0.5%
INACTIVE INGREDIENTS............99.5%
Wausau Chemical Corporation
2001 North River Drive
Wausau, WI 54403-0953 U.S.A.
| Teat Dip HP 5 hydrogen peroxide solution | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| unapproved drug other | 06/15/2010 | ||
| Labeler - Wausau Chemical Corporation (006136220) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Wausau Chemical Corporation | 006136220 | manufacture | |
ne-BIV-oh-lol
In the U.S.
Available Dosage Forms:
Therapeutic Class: Antihypertensive
Pharmacologic Class: Beta-Adrenergic Blocker, Cardioselective
Nebivolol is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled.
Nebivolol is a beta-blocker. It works by affecting the response to nerve impulses in certain parts of the body, like the heart. As a result, the heart beats slower and decreases the blood pressure. When the blood pressure is lowered, the amount of blood and oxygen is increased to the heart.
nebivolol is available only with your doctor's prescription.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For nebivolol, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to nebivolol or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Appropriate studies have not been performed on the relationship of age to the effects of nebivolol in the pediatric population. Safety and efficacy have not been established.
Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of nebivolol in the elderly.
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | C | Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women. |
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking nebivolol, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using nebivolol with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Using nebivolol with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of nebivolol. Make sure you tell your doctor if you have any other medical problems, especially:
In addition to the use of nebivolol, treatment for your high blood pressure may include weight control and changes in the types of foods you eat, especially foods high in sodium (salt). Your doctor will tell you which of these are most important for you. You should check with your doctor before changing your diet.
Many patients who have high blood pressure will not notice any signs of the problem. In fact, many may feel normal. It is very important that you take your medicine exactly as directed and that you keep your appointments with your doctor even if you feel well.
Remember that nebivolol will not cure your high blood pressure, but it does help control it. You must continue to take it as directed if you expect to lower your blood pressure and keep it down. You may have to take high blood pressure medicine for the rest of your life. If high blood pressure is not treated, it can cause serious problems such as heart failure, blood vessel disease, stroke, or kidney disease.
You may take nebivolol with or without food.
The dose of nebivolol will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of nebivolol. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
If you miss a dose of nebivolol, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
It is very important that your doctor check your progress at regular visits to make sure nebivolol is working properly and to check for unwanted effects.
Do not interrupt or stop using nebivolol without first checking with your doctor. Your doctor may want you to gradually reduce the amount you are using before stopping it completely. Some conditions may become worse when the medicine is stopped suddenly, which can be dangerous.
nebivolol may cause changes in your blood sugar levels. Also, nebivolol may cover up signs of low blood sugar, such as a rapid pulse rate. Check with your doctor if you have these problems or if you notice a change in the results of your blood or urine sugar tests.
Make sure any doctor or dentist who treats you knows that you are using nebivolol. You may need to stop using nebivolol several days before having surgery.
Before you have any medical tests, tell the medical doctor in charge that you are taking nebivolol. The results of some tests may be affected by nebivolol.
nebivolol may cause some people to become less alert than they are normally. If this side effect occurs, do not drive, use machines, or do anything else that could be dangerous if you are not alert while taking nebivolol.
Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur:
Get emergency help immediately if any of the following symptoms of overdose occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: nebivolol side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.